Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trust me we will be getting other updates soon, we should get comfortable with being on the breakout board and soon the international news.
When we hit the news we will be loaded.
There will be no way to keep this down.....
We are now on the breakout board and moving up.
I'll be using Roytoy inc. to provide meals and drinks at all the parties.
You can slip it in beside my Niceguy pleasure craft.
This will be the start of multiply PR's for cancer and we are not far off from generics and Covid therapeutics.
We are off to the races, I'm sure we will see our accounts grow with UD dollars.
Well...
Lets talk simple, this stock runs on news and then it dips until the next news update.......
Simple
I have picked up another 100K on the dips.
I know what we have and know that we will hit to 30 cent conversion rate for RBC at some point.
That is 4 times higher that the highest PPS so far.
We were up in July and we will be up again....
Remember to take profits prior to the dips.
II have a few questions as follows.
Is SBFM concerned about profitability with the recent developments of other companies?
Is there any possible update for testing and what the timeline of each stage might look like ?
Is there any update for the patents applied for?
Is there a time line for generics?
Have any discoveries of other companies possibly encroach on patents applied for ?
Is there any other company working with SBFM to bring any medications to market?
Any information you can share would be greatly appreciated
Then buy more, you know it will at least go back up to .02 in short order.
Average down for now....
I just sent them an email 5 minutes ago.
He has worked on investor relations with SBFM in the past.
I see the addition of this guy as a very positive thing, getting ready to populate the PR department.
Somebody tell Niceguy, he should be thrilled to hear.
Sunshine Biopharma, Inc 2011 Current Report 8-K - SEC.reportsec.report › Sunshine Biopharma, Inc
Jan 20, 2011 — For Additional Information Contact: CEOcast, Inc. Dan Schustack, 212-732-4300. Investor Relations. dschustack@ceocast.com. Additional Files ...
They have used this guy in the past, I see him ties to SBFM in 2011.
Seems to have a history in the pharmaceutical industry.
Well stated.
3 years and counting, we will be rewarded soon.
Keep in mind SBFM is not working on a vaccine and also the 2 vaccines proposed have yet to be proven to be effective during thorough testing.
There have been others that have made it to this point and have failed during further testing.
We are still at the forefront of therapeutics.
I feel like this will be a week to remember, updates will be closer together with larger PPS impact.
We have been patient, now get ready for the ever growing reward.
I don't think there is anyone out there with a therapeutic that is closer to human trials that will actually work for a wide spectrum of viruses.
SBFM $$$$$$$$$$$$$$$$$$$
Time to open an offshore account somewhere..........
This week is going to be exciting, some time since the last update.
I feel like this week will have some of the news we have been waiting for.
It was suggested that trials with mice should be starting in December so an update for the prior works is due.
One needs to be positioned properly for news, there will be no catching up.
Just picked up more at .013, nice dip for loading
I wouldn't want to listen to someone telling me how to run my company either.
I would imagine the patent in North America is at least as far along if not approved already.
That is my assumption.
The work seems to always be further along than we anticipate.
Once data is confirmed I's dotted and T's crossed, we will be rewarded.
Therapeutic treatment in a mouse model of MERS-CoV infection
The two best compounds (6j and 6h) in the series were examined for their in vivo efficacy using 10-week-old male hDPP4-KI mice infected with MERSMA-CoV (30). In the first study, animals were divided into three groups (n = 5 to 6) and were lightly anesthetized with ketamine/xylazine and infected with 50 µl of 750 PFU MERSMA-CoV via intranasal inoculation. Compound 6j or 6h were formulated in 10% ethanol and 90% PEG400 and given to mice from 1 to 10 dpi at 50 mg/kg per day (once per day) via intraperitoneal administration. The control mice received vehicle. Animals were weighed daily and monitored for 15 days. Animals were euthanized when an animal lost 30% of initial weight or at 15 dpi.
In the next study, treatment with compound 6j was delayed up to 3 dpi to determine the impact of delayed treatment on mouse survival. Animals were divided into five groups (n = 5), and compound 6j (50 mg/kg per day, once per day) was administered to mice starting at 1, 2, or 3 days after virus challenge (1, 2, or 3 dpi, respectively) until 10 dpi. Mice were monitored for weight loss and survival as described above for 15 days after virus challenge. As controls, vehicle (10% ethanol and 90% PEG400) was administered equivalently to the experimental compound, or animals received no treatment (untreated). The third study was conducted to assess the effects of therapeutic treatment of compound 6j in the lungs. For lung harvest and virus titration, animals were divided into three groups (n = 4) of mice, and compound 6j (50 mg/kg per day, once per day) or vehicle was administered to mice starting at 1 dpi until euthanasia. Animals were euthanized at 3 or 5 dpi, and lungs were removed aseptically, disassociated with a manual homogenizer in 1× PBS, briefly centrifuged, and supernatants removed. Samples were titered on Vero81 cells as reported elsewhere (49). For lung histopathology analyses, animals were divided into two groups (n = 5), and compound 6j (50 mg/kg per day, once per day) or vehicle was administered to mice starting at 1 dpi for 5 days. Mice were euthanized at 6 dpi, lungs were fixed with 10% formalin, and hematoxylin and eosin–stained tissues were examined by a veterinary pathologist using the postexamination method of masking (50). Briefly, tissues were scored in an ordinal manner for edema and hyaline membrane formation using the following scale: 0, none; 1, rare (<5 alveoli); 2, <33% of lung fields; 3, 34 to 66% lung fields; and 4, >66% lung fields (30).
Targeting coronavirus 3CLpro
Coronavirus 3C-like proteases (3CLpro) are attractive therapeutic targets because they play a vital role in coronavirus replication. Rathnayake et al. now report a series of optimized coronavirus 3CLpro inhibitors that blocked replication of the human coronaviruses MERS-CoV and SARS-CoV-2 in cultured cells. Administration of a lead compound to a MERS-CoV mouse model demonstrated proof-of-concept efficacy. These findings suggest that this lead compound should be investigated further as a potential therapeutic for human coronavirus infection.
Seems like the mice have been tested to some extent.
SBFM will be part of the big boards soon enough.
That is a good plan and Nice guy can tell them how to run it.
Call him and tell him how things should be done....
Simple.
The sunshine website has been updated, all part of the progression of this company and ground breaking advancements in Corona and Cancer cures.
Shhhhhh, people resting up for aggressive buying.
I think that the university is attached to funding, fairly sure I read that while surfing.
It states it is not for human or veterinary use.
I think for now it is just for scientific use and study.
If you google this you will find unlimited info on our cause.
naphthalene-based plpro inhibitors
It is endless the amount of information on the web if you search the scientific terms or the names of the university guys.
The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds
YM Báez-Santos, SES John, AD Mesecar - Antiviral research, 2015 - Elsevier
… SARS-CoV PLpro naphthalene-based inhibitors are non-toxic and highly selective for
SARS-CoV PLpro. • … CoV PLpro, the inhibition of SARS-CoV PLpro by small molecule inhibitors,
and the … demonstrated that PLpro stabilizes the NF-?B inhibitor, I?Ba, and thereby blocks the …
Cited by 246 Related articles All 12 versions
[HTML] frontiersin.org
[HTML] Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease
YK Bosken, T Cholko, YC Lou, KP Wu… - Frontiers in molecular …, 2020 - frontiersin.org
… of the novel coronavirus protease and to make comparisons to older conronavirus PLpro for which
inhibitors have been … In addition, we simulated ligand-bound trajectories of CoV1 and CoV2 PLpro
to assess potential effectiveness of one naphthalene-based and one …
All 8 versions
[PDF] acs.org
Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease
BT Freitas, IA Durie, J Murray, JE Longo… - ACS Infectious …, 2020 - ACS Publications
… naphthalene based PLpro inhibitors3, 27. To examine whether previously
developed SARS-CoV PLpro naphthalene based inhibitors might be effective at
inhibiting the SARS-CoV-2, five compounds that either had been …
Cited by 21 Related articles All 3 versions
[PDF] biorxiv.org
Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules
Z Fu, B Huang, J Tang, S Liu, M Liu, Y Ye, Z Liu… - Biorxiv, 2020 - biorxiv.org
… been reported that naphthalene-based compounds have low to zero potency towards MERS
128 … Our study suggests that focusing on the discovery of non-covalent inhibitors could be an …
screening show low potency against PLpro, we cannot rule out the potential of these drug …
Cited by 2 All 3 versions
[PDF] researchsquare.com
[PDF] Inhibition of papain-like protease PLpro blocks SARS-CoV-2 spread and promotes anti-viral immunity
D Shin, R Mukherjee, D Grewe, D Bojkova, K Baek… - 2020 - researchsquare.com
… Inhibitors of PLproCoV2, in particular naphthalene-based compounds such as GRL–0617, might
be promising … For IC50 value for inhibitors, ubiquitin-AMC was used as substrate of PLpro and
the release of AMC was … addition of 5 µl of PLpro (30 nM) to the well …
Cited by 5 Related articles All 2 versions
[HTML] nih.gov
Identification of potential inhibitors of SARS-CoV-2 papain-like protease from tropane alkaloids from Schizanthus porrigens: A molecular docking study
M Alfaro, I Alfaro, C Angel - Chemical Physics Letters, 2020 - Elsevier
… Coronaviruses, including MERS CoV [2]. Freitas et al (2020) reported that naphthalene-based
PLpro inhibitors are effective … Kandeel et al (2020) investigated PLpro use of SARS-CoV-2 to select …
Thus the objective of this work was the identification of potential inhibitors of SARS …
All 2 versions
[HTML] nature.com
[HTML] Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
D Shin, R Mukherjee, D Grewe, D Bojkova, K Baek… - Nature, 2020 - nature.com
The papain-like protease PLpro is an essential coronavirus enzyme that is required for processing
viral polyproteins to generate a functional replicase complex and enable viral spread1,2. PLpro
is also implicated in cleaving proteinaceous post-translational modifications on host …
Cited by 18 All 6 versions
[HTML] sciencedirect.com
[HTML] Crystal structure of SARS-CoV-2 papain-like protease
X Gao, B Qin, P Chen, K Zhu, P Hou, JA Wojdyla… - … Pharmaceutica Sinica B, 2020 - Elsevier
… We demonstrate that a potent SARS-CoV PLpro inhibitor GRL0617 is highly effective in inhibiting
protease activity of SARS … the past few months, several studies have reported the structures of
the SARS-CoV-2 PLpro complexed by ubiquitin, ISG15 or inhibitors; thus provided …
All 5 versions
[HTML] drugtargetreview.com
[HTML] New horizons in next-generation small molecule kinase inhibitors
K Gluza, M Dobrzanska - Drug Target Review, 2016 - drugtargetreview.com
… Webinars; Whitepapers / App Notes; Content Hubs; Events. Targets; Screening; Stem
Cells; Hit-to-Lead; Omics; Imaging; Informatics; Regs & Legs. article. New horizons in
next-generation small molecule kinase inhibitors. 62. SHARES.
Related articles
[PDF] future-science.com
Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2
S Fan, D Xiao, Y Wang, L Liu, X Zhou… - Future Medicinal …, 2020 - Future Science
… Chloroquine phosphate also could interfere with the glycosylation of ACE2 receptors, thus
inhibiting the adsorption of SARS … Both 11a and 11b exhibited high SARS-CoV-2 Mpro inhibition
activity with an IC 50 … [40] reported that naphthalene-based PLpro inhibitors seemed to be …
All of these papers were created after the patent pending date, other scientists have been involved but the process and product are under patent protection.
You need to research before you bash and even better pretend the CEO of this company is world famous for his discoveries. He did not get rich by listening to uneducated scientists.
You sir are correct sir.
I feel like a kid waiting for Christmas but in this case there is a Santa and he is bringing bags of gold to you and me...…..
Better start making space under your mattress.